(Q44637213)

4 December 2017

title

A phase II study of rebeccamycin analog (NSC-655649) in metastatic renal cell cancer (English)

1 reference

4 December 2017

1 reference

10.1023/A:1026259503954

https://api.crossref.org/works/10.1023/A:1026259503954

26 March 2024

1 reference

10.1023/A:1026259503954

https://api.crossref.org/works/10.1023/A:1026259503954

26 March 2024

2

Ulka Vaishampayan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14586215

26 March 2024

author name string

Maha Hussain

1

1 reference

4 December 2017

Vikash Jain

4

1 reference

4 December 2017

Percy Ivy

6

1 reference

4 December 2017

Lawrence Flaherty

7

1 reference

4 December 2017

Lance K. Heilbrun

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14586215

26 March 2024

Patricia M. LoRusso

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14586215

26 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14586215

26 March 2024

publication date

1 November 2003

1 reference

4 December 2017

number of pages

7

1 reference

Investigational New Drugs

inferred from page(s)

published in

1 reference

4 December 2017

volume

21

1 reference

4 December 2017

issue

4

1 reference

4 December 2017

page(s)

465-471

1 reference

One-sample multiple testing procedure for phase II clinical trials

4 December 2017

cites work

1 reference

12 December 2020

Phase I clinical and pharmacokinetic study of rebeccamycin analog NSC 655649 given daily for five consecutive days

1 reference

12 December 2020

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

1 reference

12 December 2020

Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up

1 reference

12 December 2020

Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2.

1 reference

12 December 2020

Phase I clinical and pharmacokinetic study of NSC 655649, a rebeccamycin analogue, given in both single-dose and multiple-dose formats.

1 reference

12 December 2020

Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties.

1 reference

12 December 2020

Fluorescence polarization studies of the binding of BMS 181176 to DNA

1 reference

12 December 2020

Water soluble derivatives of rebeccamycin

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1026259503954

1 reference

Dimensions Publication ID

4 December 2017

1048120713

0 references

1 reference